Zinc is a potential therapeutic for chemoresistant ovarian cancer

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 3, 2011, Pages 175-181

  Bastow, Max ^a   Kriedt, Christopher L ^a   Baldassare, Joseph ^a   Shah, Maulik ^b   Klein, Claudette ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WiseBuddha Enterprises   (United States)

Author keywords

Cell death; Chemotherapy; Ovarian cancer; Zinc

Indexed keywords

CISPLATIN; CYCLIN A; CYCLIN D; CYCLIN E; DOXORUBICIN; PACLITAXEL; ZINC; ZINC CHLORIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL KILLING; CELL NUCLEUS; CELL SHAPE; CELL SIZE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; CYCLIN A; CYCLIN D; CYCLIN E; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PYRIDINES; THIONES; TRACE ELEMENTS; ZINC;

EID: 84455163014     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ness RB, Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91: 1459-1467, 1999. (Pubitemid 29424550)
2. Pecorelli S, Favalli G, Zigliani L, Odicino F: Cancer in women. Int J Gynaecol Obstet 82: 369-379, 2003. (Pubitemid 37120520)
3. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
4. Godwin AK, Testa JR, Hamilton TC: The biology of ovarian cancer development. Cancer 71: 530-536, 1993. (Pubitemid 23021247)
5. Judson PL, Watson JM, Gehrig PA, Fowler WC, Jr., Haskill JS: Cisplatin inhibits paclitaxel-induced apoptosis in cisplatinresistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 59: 2425-2432, 1999. (Pubitemid 29242292)
6. Klein C, Creach K, Irintcheva V, Hughes KJ, Blackwell PL, Corbett JA, Baldassare JJ: Zinc induces ERK-dependent cell death through a specific Ras isoform. Apoptosis 11: 1933-1944, 2006. (Pubitemid 44691577)
7. Kriedt CL, Baldassare, JJ, Shah, M, and Klein, C.: Zinc functions as a cytotoxic agent for prostate cancer cell lines independent of culture and growth conditions. Journal of Experimental Therapeutics and Oncology 8: 287-295, 2010.
8. Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C, Baldassare J: Direct intra-tumoral injection of zincacetate halts tumor growth in a xenograft model of prostate cancer. J Exp Clin Cancer Res 28: 84-94, 2009.
9. Hashemi M, Ghavami S, Eshraghi M, Booy EP, Los M: Cytotoxic effects of intra and extracellular zinc chelation on human breast cancer cells. Eur J Pharmacol 557: 9-19, 2007. (Pubitemid 46135557)
10. Bae SN, Kim J, Lee YS, Kim JD, Kim MY, Park LO: Cytotoxic effect of zinc-citrate compound on choriocarcinoma cell lines. Placenta 28: 22-30, 2007. (Pubitemid 44767222)
11. Uzzo RG, Leavis P, Hatch W, Gabai VL, Dulin N, Zvartau N, Kolenko VM: Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 8: 3579-3583, 2002. (Pubitemid 35340736)
12. Matsui H, Oyama TM, Okano Y, Hashimoto E, Kawanai T, Oyama Y: Low micromolar zinc exerts cytotoxic action under H(2)O(2)-induced oxidative stress: Excessive increase in intracellular Zn(2+) concentration. Toxicology 30: 27-32, 2010.
13. Frederickson CJ: Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol 31: 145-238, 1989.
14. Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628, 2000.
15. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y, Wolfson M: Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ 9: 636-642, 2002. (Pubitemid 34618869)
16. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B: DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 15: 555-566, 2008. (Pubitemid 351267306)
17. Ahn HJ, Kim YS, Kim JU, Han SM, Shin JW, Yang HO: Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J Cell Biochem 91: 1043-1052, 2004.
18. Vermeulen K, Berneman ZN, Van Bockstaele DR: Cell cycle and apoptosis. Cell Prolif 36: 165-175, 2003. (Pubitemid 36808272)
19. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996. (Pubitemid 26012496)
20. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB: Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295, 2003. (Pubitemid 37487160)
21. Nogales E, Wolf SG, Downing KH: Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391: 199-203, 1998. (Pubitemid 28092482)
22. Gaskin F, Kress Y: Zinc ion-induced assembly of tubulin. J Biol Chem 252: 6918-6924, 1977. (Pubitemid 8214760)
23. Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E: Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol 57: 491-499, 2006. (Pubitemid 43087592)
24. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gercel-Taylor C: Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 65: 13-22, 1997. (Pubitemid 27171546)